Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of malignant melanoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of malignant melanoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

The introduction of immune checkpoint inhibitors such as Keytruda (Merck & Co.), Opdivo + Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; U.S. only), as well as BRAF / MEK…

The introduction of the immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; U.S. only), as well as BRAF/MEK inhibitor…

Disease stage, primary tumor resectability, and BRAF mutation status are key parameters influencing the treatment paradigm of malignant melanoma patients. BRAF/MEK inhibitor combination regimens,…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to…

The malignant melanoma market in Europe has become crowded. Small-molecule targeted therapies such as Novartis’s Tafinlar and Mekinist, monoclonal antibodies including Merck & Co.’s Keytruda…

The introduction of immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; United States only), as well as BRAF/MEK …

The treatment of BRAF mutation-positive unresectable or metastatic malignant melanoma has been transformed by the development of immune checkpoint inhibitors (e.g., Keytruda, Opdivo, Tecentriq) and…

The introduction of immune checkpoint inhibitor therapies, Keytruda (Merck & Co.) and Opdivo ± Yervoy (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combination regimens, such as Roche /…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand which drugs…

Stage of disease, resectability of the primary tumor, and BRAF mutation status are key parameters influencing the treatment paradigm of malignant melanoma. BRAF/MEK inhibitor combination regimens,…